We found that, before April 16, 2018, the first-line therapy for metastatic ccRCC predominantly consisted of TKI monotherapy, with only a small percentage of patients receiving mTOR inhibitors or PD-1/programmed cell death ligand-1 (PD-L1)-targeting therapies. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.